Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2015-A01978-41 | Other Identifier | Agence Nationale de Sécurité des Médicaments |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Institut National de la Santé Et de la Recherche Médicale, France | OTHER_GOV |
| Sys2Diag, Mixt laboratory CNRS/Alcediag, Montpellier | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Suicidal behavior (SB) is a major public health problem in France, with more than 10,000 suicides and 220,000 suicide attempts per year.
According to the commonly accepted model for understanding suicidal behavior, individuals who carry a suicidal act when subjected to stress factors (environmental stress, depression, substance ...) are those which have a specific vulnerability.
These vulnerabilities can be considered as clinical parameters (propensity to despair, aggressive and/or impulsive traits), neurobiological parameters (dysfunction of the serotonergic system, ...) and cognitive parameters (taking disadvantageous decision ...). Suicidal vulnerability is partly underpinned by genetic factors. The interest of current researches is to identify biomarkers that will improve the opportunities for early identification of subject with a risk for SB. Numerous scientific studies, including post-mortem studies of the brains of suicide completers, have established a link between dysregulation of the ribonucleic acids editing (RNA) of certain genes, the enzymatic activity of Adenosine deaminases acting on RNA (ADARS) responsible for this edition and suicidal behavior. A prospective study is needed to quantify and qualify in the blood of depressed patients (with or without a history of suicide) and healthy controls, the editing changes and the expression and alteration of the activity of ADARS.
Over two years, 600 participants will be recruited:
Each patient will attend a total of 3visits during a follow-up period of 6 months +/- 15 days (inclusion, visit at 3 and 6 months).
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Blood sample for genetic purpose | Other | All the participants performed the same evaluations and blood analysis. The study is composed of 3 groups :
|
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Blood sample for genetic purpose | Other | All the participants will performed the same evaluations and blood analysis :
|
| Measure | Description | Time Frame |
|---|---|---|
| Evolution of the modification of the expression of Adenosine deaminases acting on RNA (ADARs) and of the editing profile of phospho-diesterase 8A (PDE8A) | Studying ADARs expression and RNA editing of genes associated with SB, including PDE8A and comparison of these results between healthy controls and depressed patients with or without history of SB | At the inclusion visit, 3 months and 6 months after the inclusion |
| Measure | Description | Time Frame |
|---|---|---|
| Modification of the expression of ADAR1a enzymes | Comparison of the profiles of ADARs expression and PDE8A editing between non suicidal and suicidal depressed patients and healthy controls | At the inclusion visit, 3 months and 6 months after the inclusion |
| Modification of the expression and RNA editing of Spindle And Kinetochore Associated protein 2 (SKA2) |
Not provided
No specific inclusion criteria :
Specific inclusion criteria depressed suicide attempters:
affective controls:
healthy controls:
Exclusion criteria
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Hospital | Montpêllier | 34295 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003865 | Depressive Disorder, Major |
| D003866 | Depressive Disorder |
| ID | Term |
|---|---|
| D019964 | Mood Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D001800 | Blood Specimen Collection |
| ID | Term |
|---|---|
| D013048 | Specimen Handling |
| D019411 | Clinical Laboratory Techniques |
| D019937 | Diagnostic Techniques and Procedures |
| D003933 | Diagnosis |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
Comparison between non suicidal and suicidal depressed patients and healthy controls |
| At the inclusion visit, 3 months and 6 months after the inclusion |
| Modification of the expression of ADAR1b enzymes | Comparison of the profiles of ADARs expression and PDE8A editing between non suicidal and suicidal depressed patients and healthy controls | At the inclusion visit, 3 months and 6 months after the inclusion |
| Modification of the expression of ADAR2 enzymes | Comparison of the profiles of ADARs expression and PDE8A editing between non suicidal and suicidal depressed patients and healthy controls | At the inclusion visit, 3 months and 6 months after the inclusion |
| Modification of the expression and RNA editing of Spermidine/Spermine N1-Acetyltransferase 1 (SAT1) | Comparison between non suicidal and suicidal depressed patients and healthy controls | At the inclusion visit, 3 months and 6 months after the inclusion |
| Modification of the expression and RNA editing of Interleukins (ILs) | Comparison between non suicidal and suicidal depressed patients and healthy controls | At the inclusion visit, 3 months and 6 months after the inclusion |
| Modification of the expression and RNA editing of Chemokines (CXCLs) | Comparison between non suicidal and suicidal depressed patients and healthy controls | At the inclusion visit, 3 months and 6 months after the inclusion |
| Modification of the expression and RNA editing of Brain derived Neurotrphic factor (BDNF) | Comparison between non suicidal and suicidal depressed patients and healthy controls | At the inclusion visit, 3 months and 6 months after the inclusion |
| Modification of the expression and RNA editing of Cluster of differentiation 24 (CD24) | Comparison between non suicidal and suicidal depressed patients and healthy controls | At the inclusion visit, 3 months and 6 months after the inclusion |
| Modification of the expression and RNA editing of Three prime repair exonuclease 1 (TREX1) | Comparison between non suicidal and suicidal depressed patients and healthy controls | At the inclusion visit, 3 months and 6 months after the inclusion |
| Modification of the expression and RNA editing of Interferon stimulated gene 15 (ISG15) | Comparison between non suicidal and suicidal depressed patients and healthy controls | At the inclusion visit, 3 months and 6 months after the inclusion |
| Modification of the expression and RNA editing of Tumor necrosis factor alpha (TNF alpha) | Comparison between non suicidal and suicidal depressed patients and healthy controls | At the inclusion visit, 3 months and 6 months after the inclusion |
| Modification of the expression and RNA editing of Vascular endothelial growth factor (VEGF) | Comparison between non suicidal and suicidal depressed patients and healthy controls | At the inclusion visit, 3 months and 6 months after the inclusion |
| Modification of the expression and RNA editing of Hydroxytryptamine receptor 2A (HTR2A) | Comparison between non suicidal and suicidal depressed patients and healthy controls | At the inclusion visit, 3 months and 6 months after the inclusion |
| Modification of the expression and RNA editing of insulin-like growth factor protein 7 (IGFB7) | Comparison between non suicidal and suicidal depressed patients and healthy controls | At the inclusion visit, 3 months and 6 months after the inclusion |
| D011677 | Punctures |
| D013514 | Surgical Procedures, Operative |
| D008919 | Investigative Techniques |